Agilent Sets Fiscal Q3 Report for After the Close on Aug. 26
Agilent has a company-confirmed earnings date of Aug. 26, after the close. The shares ended Friday at 159.00, up 1.73%, ahead of a print that income-oriented holders will read closely.
Agilent Technologies has confirmed it will report quarterly results after the close on Wednesday, Aug. 26, with the shares having last changed hands at 159.00, up 1.73% on Friday, Aug. 21.
Agilent Technologies has a date on the calendar that its shareholders should mark: the company has confirmed it will publish quarterly results after the closing bell on Wednesday, Aug. 26. That places the release in the after-hours window, which means the first real price discovery happens in thin trading before most retail holders have a chance to react the following morning.
The stock (ticker: A) last traded at 159.00, up 1.73% on the session, according to market data as of 20:00 GMT on Friday, Aug. 21. The prior close was 156.30, and the shares moved between 155.24 and 160.51 during the day. Those are the last prints before the market's long weekend wait into the report.
Why the after-close slot changes how the news lands
Companies that report after the close are, in effect, handing the first read to institutional desks and algorithmic traders. The press release, the guidance revision and the segment detail all arrive at once, and the initial move is often set within minutes on volume that is a fraction of a normal session. By the time the regular market opens on Thursday, the stock has frequently already made its decision.
For anyone holding Agilent as a long-term position rather than a trade, that mechanic matters less than it appears. A single post-close gap rarely settles the investment case. But it does mean that placing a market order into the Thursday open is one of the least attractive ways to act on the news — the spread and the volatility are both at their widest precisely then.
What a life-sciences instrument maker's print actually tells you
Agilent sits in the analytical instruments and lab services corner of the healthcare complex — the picks-and-shovels layer that sells to pharmaceutical developers, contract research organisations, academic labs, environmental testing outfits and industrial chemistry customers. That customer mix makes the company a useful read-across for capital spending appetite in drug development and applied markets more broadly.
The line items that tend to move the stock in this business are recurring revenue as a share of the total — consumables, reagents and service contracts, which do not depend on customers signing off a new capital purchase — and the order book for large instruments, which does. When lab budgets tighten, instrument orders slip first and the recurring base holds up. When they loosen, the reverse. Either signal, if it shows up on Aug. 26, will carry beyond Agilent's own shares to the rest of the tools sector.
The other variable is the currency line. A company with a substantial share of revenue booked outside its home market carries a translation effect that can flatter or dent reported growth without anything changing in the underlying business. Reported versus core growth is worth separating when the numbers land.
How the tape looked going into the report
Agilent's Friday gain of 1.73% ran ahead of the broad market. The S&P 500 tracker (NYSEARCA: SPY) closed at $765.72, up 0.41% from a prior close of $762.60. The Nasdaq 100 fund (NASDAQ: QQQ) finished at $713.44, up 0.35%. The Dow 30 vehicle (NYSEARCA: DIA) closed at $532.22, a 0.89% advance and the strongest of the three benchmarks on the day.
One session does not establish a trend, and a pre-earnings drift is a notoriously unreliable predictor of what the print contains. But it is worth noting that the shares outpaced all three headline benchmarks in the final session before the report, which suggests the market was not positioning defensively into the date.
The retirement-account angle, and where it breaks down
One session does not establish a trend, and a pre-earnings drift is a notoriously unreliable predictor of what the print contains.
The framing that follows Agilent around in retirement-focused coverage — as flagged by 24/7 Wall St — rests on the idea that a diversified instruments business with a recurring revenue base is the kind of holding that suits a long-horizon account. There is something to that. Businesses selling consumables into regulated laboratory workflows have switching costs, and switching costs are what turn a cyclical equipment maker into something steadier.
Where the logic gets stretched is in treating a single earnings date as an entry or exit signal for a retirement position. If the thesis is a decade of compounding from a recurring revenue franchise, one quarter's beat or miss should not change it. If the thesis is a trade around the Aug. 26 catalyst, then it is a trade, and it should be sized as one — not parked in a tax-advantaged account under the label of a long-term holding.
A practical middle course for holders who want to act: wait for the full release and the management commentary rather than the headline number, and let the first day of regular trading establish a range before deciding. Nothing about the after-close format rewards speed for a non-professional.
Three things worth watching when the release drops
- Full-year guidance. Whether management raises, holds or trims the outlook typically matters more to the share price than the quarter just reported. A guidance change is a statement about the next several quarters; a completed quarter is history.
- The split between recurring and instrument revenue. This is the cleanest available read on whether lab customers are spending on new capital equipment or holding the line.
- Regional demand commentary. Life-sciences tools demand varies sharply by geography, and management's characterisation of each region often frames how analysts revise their models in the days after.
The date is confirmed. What arrives with it is not, and no amount of pre-positioning changes that. For holders, the question ahead of Wednesday evening is less about predicting the number than about deciding in advance what a given outcome would actually mean for the reason the position exists.
Key facts
- Earnings date: After the close, Wednesday, Aug. 26 (company-confirmed)
- Agilent (A) last price: 159.00, +1.73%, as of 20:00 GMT, Fri, Aug. 21, 2026
- Prior close / day range: 156.30; traded 155.24–160.51
- Benchmarks that session: SPY $765.72 (+0.41%), QQQ $713.44 (+0.35%), DIA $532.22 (+0.89%)
Frequently asked questions
When exactly does Agilent report?
Agilent Technologies has confirmed its quarterly earnings release for after the close on Wednesday, Aug. 26. Because it lands in the after-hours session, the first significant price reaction typically occurs in extended trading that evening rather than during the following regular session's open, when volume and spreads are less favourable for smaller investors.
Where did Agilent shares finish before the report?
The stock last traded at 159.00, a gain of 1.73% on the day, as of 20:00 GMT on Friday, Aug. 21, 2026. The previous close was 156.30 and the intraday range ran from 155.24 to 160.51. That was the final print before the market's wait into the Aug. 26 release.
How did Agilent perform against the broad market that day?
Agilent's 1.73% gain outpaced all three headline benchmark funds on the same session. The S&P 500 tracker closed at $765.72, up 0.41%; the Nasdaq 100 fund at $713.44, up 0.35%; and the Dow 30 vehicle at $532.22, up 0.89%. A single session, however, is not a reliable predictor of an earnings outcome.
What does Agilent's business actually do?
Agilent operates in analytical instruments and laboratory services, supplying pharmaceutical developers, contract research organisations, academic institutions, environmental testing labs and industrial chemistry customers. Its revenue splits between one-time instrument sales and a recurring stream of consumables, reagents and service contracts, the latter of which tends to be more resilient when customer capital budgets tighten.
Which figures in the release matter most?
Full-year guidance usually moves the share price more than the completed quarter, because it speaks to future periods rather than history. The split between recurring revenue and new instrument sales indicates whether lab customers are committing capital. Regional demand commentary shapes how analysts revise their models in the days after the release.
Should a retirement investor trade around the earnings date?
An earnings date and a long-horizon holding are different propositions. If the position exists because of a multi-year thesis about recurring revenue and switching costs, one quarter's result should not change it. If the intent is to trade the catalyst, it should be sized and treated as a trade rather than a core retirement allocation.
Sources
Photo: Mikhail Nilov · Pexels Licence — source
